 |
|
The Course, Morbidity, and Costs of Depression
Gerald L. Klerman, MD;
Myrna M. Weissman, PhD
Arch Gen Psychiatry. 1992;49(10):831-834.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Eight independently conducted studies that were begun more than a decade ago when the morbidity of major depression, its clinical course, long-term treatment, and impact on children were unclear are reported in this issue of the ARCHIVES.1-9 Using different sampling, different levels of severity of depression, different types and lengths of treatment, and patients of different ages, these studies provide an overview and replication of findings on course, morbidity, costs, and treatment of major depression. Cumulatively, the findings clearly show that depression is not ubiquitous, trivial, or transient. If the scope of outcome is broadened to include relapse, recurrence, comorbidity, chronicity, impact on family, absenteeism, and work productivity, it may not be humane, prudent, or economical to limit the identification of depression or shorten its course of treatment. This view may at first seem at variance with current efforts to reduce escalating health care costs or to manage cases.
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Psychiatry, Cornell University Medical Center, Payne Whitney Psychiatric Clinic (Dr Klerman), the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the Division of Clinical and Genetic Epidemiology, New York State Psychiatric Institute (Dr Weissman), New York.
Footnotes
Accepted for publication July 20, 1992.
Dr Klerman died April 3, 1992.
Reprint requests to Division of Clinical and Genetic Epidemiology, New York State Psychiatric Institute, 722 W 168th St, Box 14, New York, NY 10032 (Dr Weissman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
